Hemostasis Today

April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Abdul Mannan: A Practical Guide to Anticoagulation Stewardship
Mar 4, 2026, 14:36

Abdul Mannan: A Practical Guide to Anticoagulation Stewardship

Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:

“Most anticoagulation errors don’t happen because doctors don’t know the drugs.

They happen because nobody built a system around the prescription.

I’ve spent years watching patients bleed or clot because of one missing step.

The indication wasn’t documented. The renal function wasn’t rechecked. The duration was never reviewed.

Nobody asked: does this patient still need this?

That’s not a knowledge problem. That’s a stewardship problem.

So I built something to fix it.

My new Anticoagulation Stewardship reference covers everything in one place:

The 5R Framework:

  • Right drug
  • Right dose
  • Right indication
  • Right duration
  • Right monitoring

DOAC vs Warfarin: Head-to-head comparison with renal dosing tables for apixaban, rivaroxaban, dabigatran and edoxaban

Risk scoring: CHA₂DS₂-VASc, HAS-BLED, Khorana — with the one teaching point about HAS-BLED that every trainee gets wrong

Step-by-step decision algorithm: From indication confirmation to monitoring plan

Reversal agents: Idarucizumab, andexanet alfa, PCC, protamine — with exact dosing and trial evidence

Stewardship checklist: For both initiation and every review visit

One thing I want you to remember:

A high HAS-BLED score is not a reason to stop anticoagulation in AF. It is a reason to fix the modifiable bleeding risks.

Treat the BP. Stop the NSAIDs. Switch to a DOAC if the INR is unstable.

The stroke risk almost always wins.

Built for trainees, juniors, nurses, pharmacists and anyone who touches an anticoagulant prescription.

What’s the anticoagulation stewardship gap you see most often in your practice?”

Other posts featuring Abdul Mannan on Hemostasis Today.